(Q40238563)

18 September 2017

Future directions in tumor immunotherapy: CTLA4 blockade (English)

1 reference

18 September 2017

1 reference

1 reference

1

James L Gulley

1 reference

18 September 2017

William L Dahut

2

1 reference

18 September 2017

1 March 2007

1 reference

Nature Clinical Practice Oncology

18 September 2017

1 reference

18 September 2017

4

1 reference

18 September 2017

3

1 reference

18 September 2017

136-137

1 reference

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

18 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0749

Multiple costimulatory modalities enhance CTL avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0749

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0749

7 January 2021

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0749

7 January 2021

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0749

7 January 2021

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0749

7 January 2021

Identifiers

DOI

10.1038/NCPONC0749

1 reference

18 September 2017

1 reference

PubMed ID

17327854